Latest Industry Insights

At ELRIG’s Research & Innovation 2024 event, Technology Networks spoke to Dr. Véronique De Conto, project leader in in vitro pharmacology at HCS Pharma, to learn more about their powerful tools for in vitro metastasis propagation.

At the European Laboratory Research and Innovation Group’s (ELRIG) Research and Innovation 2024 event, we asked a selection of start-up companies in the biotech space the same question: what are the key challenges you currently face?

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”

In this interview, Dr. Mason tells us about her career path and experiences along the way, as well as sharing advice for women considering a career in science.

In this opinion piece, Amy Butler shares her career path from lab to leadership, including how she was able to rise up in the ranks despite being an introvert.

While traditional methods of cell sorting come with several challenges, microbubbles are simple to use and can separate cells without causing harm. Technology Networks spoke to Dr. Brandon McNaughton, CEO and co-founder of Akadeum to find out more about this technology, its applications and how it could improve cancer treatment.

As the use of generative AI tools expands, and their potential in scientific research is better understood, there are ethical considerations to be made. Dr. Dror Kolodkin-Gal explores some of the issues and potential solutions.

Explore how advances in food cultivation techniques make safer food alternatives possible while allowing marine wildlife to remain in the ocean to restore and replenish their populations.

In this interview, Dr. Tabitha Bullock tells us about some of the key considerations in cell line development and how advances in technology are improving the efficiency and productivity of cell lines.

Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.